2nd European Neurotech & Investing Partnering Summit
Preliminary Agenda
Wednesday September 4, 2013
7:30 Breakfast & Registration
8:30 Welcome and The Global Neurotechnology Industry 2013
Casey Lynch, Managing Director, NeuroInsights
9:00 Investing in Neurotech - Panel Discussion
A diverse panel of private, public and strategic investors will discuss their investment strategies. What are investors looking for to balance the risks and opportunities in neurotech? What are the benefits of business models in devices, pharmaceuticals, diagnostics and information technology in the EU? What are today's deal terms and valuations? What are the best exit strategies and how is neurotech comparing to other industries?
Moderator: Killu Sanborn, Dir. Business Development, Oxford Finance
Johan Christenson, Partner, Healthcap
Johan Kördel, Senior Partner, LundbeckFond
Soren Moller, Managing Investment Director, Novo Seeds
10:00 Networking and Refreshment Break
10:30 Alzheimer's and Cognitive Disorders
As the population ages, the market for Alzheimer's and cognitive disorders is exploding. Current treatments stabilize symptoms only for a short period of time. What is on the horizon for symptom improvement and disease modification from drug and device companies?
Session Chair: Christian Hordo, Senior Manager Business Development, Genentech
Bjorn Larsson, Executive Chairman, Alzinova
Hendrik Leibers, CFO, Probiodrug
Koen de Witte, Managing Director, reMYND
Gerald Commissiong, President & CEO, Amarantus Bioscience
11:30 Strategies for CNS Drug and Device Development
Intelligent preclinical screening and clinical trial design is critical to the success of any neurotech venture. The moderator will lead an insider panel in a discussion of specific tactics for improving drug and device development to navigate a path to approval. Case studies will demonstrate lessons learned in Alzheimer's, Parkinson's, depression, pain and more.
Session Chair: Zack Lynch, Executive Director, Neurotech Industry Org
Leonard Khiroug, Chief Scientific Officer, NeuroTar
Alan Mock, VP of Commercialization, GreatBatch QIG Group*
12:30 Lunch
2:00 Movement Disorders: Parkinson's, ALS and more
Exciting developments are in the pipeline for slowing progression of some of the most vexing neurological conditions like ALS, Huntington's and Parkinson's. What is the latest science behind new targets for these disorders. Can active doctor and patient populations and high prices offset small markets in orphan indications? Can early improved diagnosis and treatment tracking improve outcomes?
Session Chair: Alexandra Goll, General Partner, TVM Capital
Jean-Pierre Rosat, Co-founder and CEO, Aleva Neurotherapeutics
Kyle Gano, Vice President Business Development, Neurocrine Biosciences
Serge Kinkingnehun, Founder & CEO, E(ye)brain
Andres Montefeltro, CEO, nLife Therapeutics
3:00 Internal and External Research & Development
What is in the pipeline at Big Pharma, Biotech and Medtech? Where are companies focusing internal versus external resources? How can out-licensing and spin out opportunities be leveraged? What opportunities exist for discovery partnerships and early development collaborations?
Moderator: Patrick Krol, Managing Partner, Aescap Venture*
Pierandrea Muglia, VP & Head Neuroscience Disc, UCB Pharma
Declan Jones, Neuroscience Therapeutic Area Lead, Johnson & Johnson Innovation
Imran Eba, Director, Investment Management, WW Business Development, GlaxoSmithKline
4:00 Networking and Refreshment Break
4:30 Acute and Traumatic Injury: Stroke and TBI
New hope is emerging for treatments of major traumatic injuries to the central nervous system. While highly challenging, companies are leveraging innovative financing to address these unmet markets.
Session Chair: Andreas Jeromin, President, Atlantic Biomarkers
Ulf Pommerening, CEO, EBS Technologies
Eamon Brady, CEO, Neuravi
Janne Huhtala, CEO, Nexstim
Kent Pryor, COO, ZZ Biotech
5:30 Networking Reception
Thursday September 5, 2013
7:30 Breakfast & Registration
8:30 Creating a Rising Tide for the Brain Industry
Zack Lynch, CEO, Neurotech Industry Organization
John Reppas, Director of Public Policy, Neurotech Industry Organization
8:50 Partnering, Licensing and Acquisitions in Neurotech
Big pharma, biotech and medtech are increasingly looking to smaller firms to provide innovative product candidates to fill pipelines. What are current trends in licensing and acquisitions? What are priority indications and stage of development requirements? What are the opportunities for neurodevice companies and who is interested in acquiring novel technology?
Moderator: Frank Eeckman, Managing Director, Woodside Capital Partners
Erik Lund, Director Worldwide Licensing, MSD (Merck)
Klaus Mendla, Global Head, CNS BD & Licensing, Boehringer Ingelheim
Jeff Erb, Senior Director, Business Development, Alliances, & IP Portfolio Mgmt, Medtronic
10:00 Networking and Refreshment Break
10:30 Frontiers in Neurotechnology
Companies present novel approaches to tackling the brain and nervous system including brain mapping technology, neuromodulation platforms, diagnostic software, blood brain barrier penetration, and simulation technology for drug development.
Session Chair: Thom Rasche, Partner, Early Bird Ventures
Peter Crosby, CEO, Mainstay Medical
Juhani Lahdenperä, CEO, Hermo Pharma
Andreas Hartlep, CEO, Cerbomed
Ana Maiques, CEO, Neuroelectrics*
11:30 Next Generation Psychiatry
Schizophrenia, anxiety, depression, ADHD, and other psychiatric illnesses represent a large portion of the neurotech market. What are the most promising next generation treatments? How will devices and diagnostics change the treatment landscape?
Anthony McKinney, CEO, Euthymics & NeuroVance
Blake Paterson, CEO, Cerecor
Erik Buntinix, CEO, Pharmaneuroboost
12:30 Lunch
2:00 Cutting Edge Translational Research
This session will feature selected cutting-edge research projects and licensing opportunities from academia and research institutes. How do these novel projects shift the future of CNS treatment development? Where should research be headed to avoid the problems of past generation therapeutics and devices?
Eero Castren, Director, Neuroscience Center, University of Helsinki
3:00 Refreshment Break, One-on-One Meetings
5:00 Conference Concludes
